Research & Development: Page 56
-
PharmaVoice Team/PharmaVoice
New Course for Biotherapeutics
Denise Myshko Companies developing biotherapeutics are beginning to study indications beyond cancer and autoimmune and infectious diseases and are researching how antibodies and proteins can be used to treat other conditions, such as pain and cardiovascular conditions, that have traditionally bee...
By Denise Myshko • April 27, 2012 -
PharmaVoice Team/PharmaVoice
Last Word
Word Building Strong Partnerships John Gargiulo, President and CEO of Daiichi Sankyo Inc., talks about how a philanthropic gift 100 years ago led to a global collaboration for drug development. PV: What is Daiichi Sankyo’s connection to Washington, D.C.’s cherry trees? Gargiulo: One hundred year...
By Carolyn Gretton • April 27, 2012 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Talent Pool
Talent Pool executive appointments and promotions in the healthcare industry By Carolyn Gretton Pharmaceutical POOL Dr. Charlotte KREMER Astellas Names Global Medical Affairs Head Charlotte Kremer, M.D., has joined Astellas Pharma as head of the global medical affairs organization. Dr. Kremer wa...
By Carolyn Gretton • April 27, 2012 -
PharmaVoice Team/PharmaVoice
Tools of the Trade
Tools of the Trade New electronic and web-based applications, sites, and technologies By Carolyn Gretton New Tool from HealthSTAR Provides Virtual Bridge Between KOLs, HCPs Trend: New advances in digital platforms are allowing for the capture of peer-to-peer programs via a digital platform that ...
By Carolyn Gretton • April 27, 2012 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Pharma Trax Sales, marketing, And R&D?Trends affecting the healthcare industry By Carolyn Gretton GSMA Forecasts Robust Mobile Health Market Growth Areport conducted by PwC for the GSMA predicts the growth of the mobile health (mHealth) market will result in $23 billion worth of revenue oppor...
By Carolyn Gretton • April 27, 2012 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: IRBs: Remaking the Rules
By Carolyn Gretton Institutional review boards (IRBs) and research compliance offices remain at the forefront of providing responsible protection of human subjects within the research environment, but the differences in how each group interprets and implements these responsibilities can directly ...
By Carolyn Gretton • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Global Patient Recruitment
Robin Robinson Social media, regulations, and outsourcing are shaping global trial recruitment models. According to a recent CEI survey, more than 20% of responding companies use text messaging for patient visit reminders in Phase I through Phase III. Source: Cutting Edge Information As is tru...
By Taren Grom • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Clinical Trial Technology Continues to Evolve
By Denise Myshko Electronic processes for data collection are now widely used in clinical trials. But the use of technology and electronic processes for the operational side of trials is still lagging. Ten years ago, when PharmaVOICE first started writing about clinical trial technologies, elect...
By Denise Myshko • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Patient Communities: Getting to Know You
Patient Communities: Getting to Know You By Robin Robinson The industry is tapping into the wealth of market research available through patient communities. In 2010, UCB and PatientsLikeMe launched a patient community designed as an online forum for epilepsy patients to share their experiences in...
By Robin Robinson • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Last Word
The Promise of Stem Cell Therapies for Chronic Diseases Andrew Pecora, M.D., Chief Medical Officer and Director at Neostem, discusses the company’s work using stem cells for cardiovascular conditions. The company’s lead product candidate, AMR-001, is for the preservation of heart function after a...
By Dr. Andrew Pecora • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Talent Pool
executive appointments and promotions in the healthcare industry By Carolyn Gretton Pharmaceutical POOL Dr. Rob KOREMANS Former Sanofi VP Takes Lead Role at Teva Europe Teva Pharmaceutical Industries has appointed Rob Koremans, M.D., to succeed Dr. Gerard van Odijk as president and CEO, Teva Euro...
By Carolyn Gretton • March 26, 2012 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D?Trends affecting the healthcare industry Study Explores How Consumers Interact With Pharma Companies Trend: Growing numbers of patients are turning to social media and digital tools to obtain drug information before meeting with their physicians, representing a key ...
By Carolyn Gretton • March 26, 2012 -
PharmaVoice Team/PharmaVoice
What's New
New healthcare-related products, services, and companies Transparency Life Sciences Launches with Open Innovation-Based Model Trend: This new breed of drug development company aims to achieve much greater efficiency in its patient-centric trials by harnessing the power of collaborative intellige...
By Carolyn Gretton • March 26, 2012 -
PharmaVoice Team/PharmaVoice
UpFront
Upfront Awards… CSL Honored for Work in Rare Diseases CSL Behring is the recipient of a 2012 European Organization for Rare Diseases Award for its work in developing and manufacturing therapies used to treat rare and serious medical conditions. One of the primary criteria for the award is a...
By Taren Grom • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The forum for the industry executive Volume 12 • Number 4 Publisher Lisa Banket Editor Taren Grom Creative Director Marah Walsh Managing EDitor Denise Myshko Senior EDitor Robin Robinson features EDitor Kim Ribbink Contributing Editor Carolyn Gretton design associate Ariel Medel national account ...
By Taren Grom • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Germany: A Market for Clinical Research
G ermany is a pre-eminent pharmaceutical market. In 2008, for example, the German pharmaceutical industry comprised 243 companies, employed 126,000 people, and generated EUR 41.5 billion ($53.8 billion) in revenue, according to Germany Trade & Invest, a German investment agency. Germany is th...
By Kim Ribbink • Feb. 27, 2012 -
PharmaVoice Team/PharmaVoice
Payers Play Larger Role In PostLaunch Strategies
The focus of postlaunch activities has changed dramatically in just a few short years. Robin Robinson Due to the increased power of payers and managed care companies, Phase IV studies have become more imperative to sustaining a successful postlaunch campaign. Companies have had to reprioritize th...
By Robin Robinson • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Rising Costs Are Top of Mind in Phase III
The good news: more drugs are entering Phase III trials. The bad news: clinical trial costs continue to rise. The number of drugs in Phase III development in 2011 increased by 13%, representing the largest year-over-year improvement seen, according to Citeline’s 2011 Annual Review of Trends in Ph...
By Denise Myshko • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Creating the Message in Phase II Trials
Decisions made in Phase II trials can have an impact on the development and marketing program for new products, and experts say Phase II is becoming a critical stage for planning the potential launch and marketing of products. Bringing agencies in earlier in the process makes a lot of sense, says...
By Denise Myshko • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
New Models for Early Development
The number of drugs entering Phase I fell 47% and the number of drugs entering Phase II trials fell 53%, according to 2011 Pharmaceutical R&D Factbook complied by CMR International. Industry experts say there is a trend toward conducting fewer, more complex early-phase studies that often incl...
By Denise Myshko • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Achieving Value from Discovery and Preclinical Endeavors
The need to increase value and productivity throughout the development process has never been more critical. R&D expenditure continued to drop in 2010 to an estimated three-year low of $68 billion, and drug success rates continue to show the declining trends of the past decade, according to t...
By Denise Myshko • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Molecule to Market - Along the Continuum
According to the most recent report from Tufts Center for the Study of Drug Development, it still takes about 10 to 15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. Only one ...
By Taren Grom • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Dr. Anders EKBLOM Dr. Briggs MORRISON AstraZeneca Bolsters R&D Leadership Global pharmaceutical company AstraZeneca has tapped Anders Ekblom, M.D., to build and lead the science and technology integration office within the company’s R&D organization. In addition to th...
By Carolyn Gretton • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: Kantar Health Focuses on Cancer Patients’ Healthcare Decision-Making Aerpio Therapeutics Makes Debut In other news… Inspiration Biopharmaceuticals Moves Corporate Headquarters AROUND THE GLOBE Kantar Health, a healthcare-fo...
By Carolyn Gretton • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Long-Term Planning Tactics Key to Maintaining Portfolio Health Sidebar: Groups Responsible for Aligning Brand and Corporate Strategy Therapeutic Fast Trax… Other market insights… Brand Positioning Should Balance PR, RO...
By Taren Grom • Feb. 26, 2012
Previous
